Does ADT benefit unfavourable intermediate risk prostate cancer patients treated with brachytherapy boost and external beam radiotherapy? A propensity-score matched analysis

The addition of androgen deprivation therapy (ADT) to radiotherapy (RT) is the standard of care for prostate cancer patients with unfavourable intermediate risk (UIR) and high-risk disease. In this population, ADT has been shown to improve oncological outcomes by increasing RT local effect [1 –3] and likely by reducing the micrometastatic burden. Although the role of ADT in high-risk prostate cancer patients is firmly established, the benefit associated with this therapy in UIR patients treated with dose-escalated RT is less well defined [4,5].

Source: Radiotherapy and Oncology - June 29, 2020 Category: Radiology Authors: Lucas C. Mendez, Kevin Martell, Andrew Warner, Chia-Lin Tseng, Hans Chung, Andrew Loblaw, George B. Rodrigues, Gerard Morton Source Type: research